These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 35108125

  • 1. Clinical Efficacy and Safety of Fanhdi®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study.
    Jiménez-Yuste V, Alvarez-Román MT, Palomo Bravo Á, Galmes BJ, Nieto Hernández MDM, Benítez Hidalgo O, Marzo Alonso C, Pérez González NF, Coll J, Núñez R, Carrasco M, García Candel F, Gonzalez-Porras JR, Hernández García C, Varó Castro MJ, Mir R.
    Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
    [Abstract] [Full Text] [Related]

  • 2. Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
    Federici AB, Santoro RC, Santoro C, Pieri L, Santi RM, Barillari G, Borchiellini A, Tosetto A, Zanon E, De Cristofaro R, Mairal E, Mir R.
    Clin Appl Thromb Hemost; 2024; 30():10760296241264541. PubMed ID: 39033425
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R.
    Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannuccio Mannucci P.
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
    Batty P, Chen YH, Bowles L, Hart DP, Platton S, Pasi KJ.
    Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease.
    Rugeri L, Thomas W, Schirner K, Heyder L, Auerswald G.
    Thromb Haemost; 2024 Sep; 124(9):828-841. PubMed ID: 38272065
    [Abstract] [Full Text] [Related]

  • 14. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E, Windyga J, European Wilate Study Group.
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.
    Howman R, Barnes C, Curtin J, Price J, Robertson J, Russell S, Seldon M, Suppiah R, Teague L, Barrese G.
    Haemophilia; 2011 May; 17(3):463-9. PubMed ID: 21118340
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
    Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M.
    Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
    [Abstract] [Full Text] [Related]

  • 20. Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment.
    Hazendonk HCAM, Heijdra JM, de Jager NCB, Veerman HC, Boender J, van Moort I, Mathôt RAA, Meijer K, Laros-van Gorkom BAP, Eikenboom J, Fijnvandraat K, Leebeek FWG, Cnossen MH, “OPTI-CLOT” and “WIN” study group.
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.